Hepatitis C Ricardo Baptista Leite-Books Download

30 Nov 2019 | 48 views | 0 downloads | 20 Pages | 823.68 KB

Share Pdf : Hepatitis C Ricardo Baptista Leite

Download and Preview : Hepatitis C Ricardo Baptista Leite

Report CopyRight/DMCA Form For : Hepatitis C Ricardo Baptista Leite


to the HEPATITIS C Community Summit,from 18 19 April in Amsterdam. BRIDGING THE GAP BETWEEN,RESEARCH HARM REDUCTION TREATMENT. AND PEOPLE LIVING WITH HEPATITIS C, On behalf of Correlation Network Organising Committee it is our pleasure to welcome you to the Hepatitis C. Community Summit In the next two days a great number of excellent plenary speeches and abstracts will be. We are facing exciting opportunities With the new medicines now available an opportunity exists to comple. tely eradicate hepatitis C However it will require pharmaceutical companies governments doctors and. health purchasers to come together to ensure these medicines are quickly available to all Also a crucial. factor for success will be the involvement of people living with hepatitis C. The implementation of harm reduction and low threshold community based services providing access to. testing and treatment as well as effective prevention interventions will be critical to ensure the treatment of. high risk groups such as people who inject drugs men having sex with men and immigrants. This summit aims to create an opportunity for a variety of stakeholders to come together and bridge the. gap that exists between what is our current reality and what can be our reality a world where hepatitis C is. eradicated,Organising Committee,Correlation Network Hepatitis C Initiative. European Aids Treatment Group EATG, European African Treatment Advocates Network EATAN.
European Network of People Who Use Drugs EURONPUD,European Liver Patient Association ELPA. International Doctor for Healthier Drug Policy IDHDP. AFEW International,Alliance for Public Health Ukraine. Prometheus Association Greece, The organising committee would like to extend a special thanks to the sponsors of the. Hepatitis C Community Summit,Koninklijke Industrieele Groote Club. 1012 JS Amsterdam,Venue Abbvie Lunch Session,Eggertzaal.
Eggertstraat 8,1012 NN Amsterdam,Hospitality Desk, The hospitality Desk will be located on the Ground Floor at the Reception near the entrance Here you can. register for parallel sessions if you haven t done so pick up your name tag and ask any questions on the. conference itself,Emergency contact, For any logistical issues or questions please contact. Natacha Berbers 31657345785, Free wireless information is available at the venue using the login codes below. Network Koninklijke IGC,Password amsterdam1012,Tuesday 18 04 2017. 13 30 14 30 Coffee and registration,14 30 15 00 Opening and welcome.
Location Central Hall,Chair Eberhard Schatz Correlation Network. Welcome word, Stephen Malloy European Network of People Who Use Drugs. Denis Onyango European African Treatment Advocates Network. Welcome address and EASL recommendations on the treatment of HCV. Frank Tacke European Association of the Study of the Liver. Hepatitis C policy and care needs involving of all turn the page. Graham Foster Queen Mary University of London,15 00 16 00 Plenary speeches. Location Central Hall,From data collection to recommendation. Philippa Easterbrook Global Hepatitis Programme World Health Organisation. From recommendation to practice Access to testing and treatment in Europe. Mojca Maticic Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre Ljubljana. From peer to research, Magdalena Harris London School of Hygiene and Tropical Medicine.
From patient to advocate, Anton Basenko International HIV AIDS Alliance in Ukraine. 16 00 16 30 Coffee break,16 30 17 15 Round table discussion. Location Central Hall,Moderator Chris Ford IDHDP, Experiences to treat risk groups in a barrier free low threshold setting. With the complete eradication of hepatitis C now possible with new treatments we need to think how best to get these. medicines to all the people who need them This round table discussion will look at 3 experiences of providing testing. and treatment of hepatitis C from within a community based setting from Scotland France and Austria Following the. brief presentations there will be an open discussion to examine opportunities for more barrier free treatment making. testing and treatment available and accessible to all Delegates are welcome to talk about their own experiences. John Dillon University of Dundee Scotland,Vo Tran GAIA Paris. Hans Haltmayer Suchthilfe Vienna,17 15 18 15 Round table discussion.
Location Central Hall,Moderator Ricardo Bapista Leite. Member of National Parliament Portugal Head of Public Health Cat lica University of Portugal. A politician interviews experts from different areas Elimination can we make it. Jason Grebely The Kirby Institute UNSW Sydney from a research perspective. Daniel Sim es EATG from a community perspective, C line Grillon M decins du Monde from an advocacy perspective. Maka Gogi HR network Georgia experiences on elimination in Georgia. 18 15 19 00 Reception,Wednesday 19 04 2017,09 30 11 00 Plenary session. Location Central Hall, Chairs Magdalena Harris LSHTM George Kalamitsis Prometheus Association. Engaging Migrants barriers to testing and treatment. Mesfin Ali Embrace UK Community Support Centre London A6. Thirty years of harm reduction in the Netherlands HCV elimination ahead. Esther Croes Trimbos Institute Utrecht A7,Hepatitis in prison settings.
Heino St ver University of Applied Science Frankfurt A8. Access in EECA countries, Natalia Kravchenko Alliance for Public Health Kiev A9. 11 00 11 30 Coffee break,11 30 13 00 Abstract driven sessions overview. Parallel session 1 Parallel session 2 Parallel session 3. Location Damzaal Location Bibliotheek Location Bestuurskamer. Chair John Peter Kools Chair Sebastian Saville Chair Denis Onyango and Julia del. The treatment cascade Reach your crowd, Good practices from a diversity Innovative tools and methods for. of countries on how HCV testing HCV awareness and information On the move Infectious diseases in. outreach and treatment is organised migrant populations. in harm reduction settings,A10 A11 A12 A13 A14 A15 A16 A17 A18. 13 00 14 30 Lunch, Lunch will be served in the hall of the venue vegetarian options are available.
13 00 14 30 Lunch time session,Location Eggertzaal. Path to Zero, Fresh thinking on the road to eliminating Hepatitis C. This session will bring together representatives from around the world to explore actionable ways to raise awareness. of finance initiatives to and put knowledge into practice to help eliminate HCV The session will have a specific focus on. the Path to Zero a program developed by the Economist Intelligence Unit EIU and sponsored by AbbVie which aims. to enhance awareness of and initiate a global dialogue around innovative solutions toward eliminating the disease It. will feature a panel discussion with ground breaking innovators or HCV Change Makers to present case studies and. explore new strategies to affect real change The EIU will moderate the session which is sponsored by AbbVie. Lunch will be provided, pre registration required max participants 40 persons. 13 00 14 30 Lunch time session,Location Dameszaal,Chair Anke van Dam AFEW. How to give Hep C and harm reduction a better profile at AIDS2018 Brainstorm session on topics speakers. and other preparations for the international AIDS conference in Amsterdam next year. Lunch will be provided, pre registration required max participants 12 persons.
14 30 16 00 Abstract driven sessions overview, Parallel session 4 Parallel session 5 Parallel session 6. Location Damzaal Location Bibliotheek Location Bestuurskamer. Chair Katrin Schiffer Chair Achim Kautz Chair Ludmila Maistat. Peer work as a key role in all phases Best practice examples in different Availability and pricing examples. of the process prevention testing areas of HCV counseling screening of effective advocacy for affordable. and access to care and monitoring DAA s,A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A29 A30. 16 00 16 30 Coffee break,16 30 17 30 Plenary session. Location Central Hall,Chair Marko Korenjak ELPA, The 2016 Hep CORE Report Monitoring European policy responses to viral hepatitis. Jeff Lazarus Rigshospitalet University of Copenhagen and ELPA members from 5 countries. Community Declaration, Presented by Magda Ferreira peer worker at GAT Lisbon.
18 00 20 00 Final Networking Session reception,Location Central Hall. WRAP UP video conference prepared by Igor Kouzmenko Drug User News Kiev. Julian Hows GNP What can we learn from the HIV AIDS movement. Khalid Tinasti Global Commission on Drugs presents the work of the Commission on Hepatitis and intro. duces the VIDEO message of Professor Michel Kazatchkine former Executive director of the Global. Fund to fight AIDS tuberculosis and malaria, Ricardo Bapiste Leite Member of National Parliament Portugal presents Hepatitis C Policy in Action. Abstract per presentation and session, A1 Hepatitis C policy and care needs involving of all turn the page. Graham Foster Queen Mary University of London London. Chronic hepatitis C infection has wreaked havoc among those who use drugs For far too long therapy has involved unpleasant. poorly effective medicines that have been unpopular with patients and their doctors The last two years has seen a transformation. in treatment options and we now have tablet only therapies that are side effect free and cure over 90 of those who are infected. Clinical trials have demonstrated their efficacy in those who are actively using drugs and many countries are now beginning. major public health campaigns to treat all who are infected with HCV and eliminate this virus from our planet However among. the optimist and hope brought by the new drugs is the ever present menace of discrimination and selection of the worthy in. some American states drug users are denied access to opiate substitution therapy and needle exchange but when they die from. their drug overdoses the American medical system springs into life to harvest their organs to transplant into others who can then. undergo treatment for the hepatitis C that is inevitably transmitted with the new organ To maximise the benefits from the opportu. nities offered by the new drugs will require a commitment to evidence based treatment for all. A2 From data collection to recommendation, Philippa Easterbrook Global Hepatitis Programme World Health Organisation. A core function of WHO Global Hepatitis Programme is the provision of evidence based guidance in hepatitis prevention care. and treatment particularly for low and middle income countries Key recent care and treatment guidelines include for hepatitis C in. 2016 and hepatitis B in 2015 and most recently testing for viral hepatitis in 2017 The presentation will summarise the key new. WHO recommendations and how these relate to higher risk populations as well as the WHO guidelines process i e how we. decide on the topics review and rate the quality of evidence and formulate recommendations based not just on the evidence but. on considering cost cost effectiveness feasibility and acceptability The critical role of civil society in the guidelines process will. be highlighted, A3 From recommendation to practice Access to testing and treatment in Europe.
Mojca Maticic Clinic for Infectious Diseases and Febrile Illnesses University Medical Centre Ljubljana Ljubljana. Hepatitis C virus HCV infection is the leading cause of cirrhosis end stage liver disease and hepatocellular carcinoma To date. among the estimated 130 150 million of infected worldwide 75 have not yet been tested for HCV infection and only 3 5 have. received HCV treatment In European region people who inject drugs PWID represent the majority of infected and the propor. tion of those who were tested and treated for HCV varies among countries The first recommendations on the management of. HCV infection set up by the international expert societies in the late nineties were restrictive to HCV treatment in PWID due to. several barriers which over the years proved to be unjustified In recent years studies have shown that in PWID HCV testing and. treatment work to prevent of spreading the infection and modelling studies suggested that they could reduce prevalence and. incidence of HCV infection as well as disease burden among PWID A viral hepatitis resolution approved by the World Health. Assembly in 2014 called on all countries to develop and implement national strategies for preventing diagnosing and treating viral. hepatitis After that PWID were recognized as a group that should get HCV testing and treatment including direct acting antivirals. DAAs in all the international recommendations, A study of 27 European countries performed by European Liver Patient Association ELPA in 2016 has shown some improve. ments in testing for HCV infection In some countries HCV testing has become available for general population and high risk po. pulations including PWID and it has become included in routine screening as well as performed at various screening sites outside. the medical settings however the data vary immensely among the European countries. In 2016 a first study evaluating the real life realization of the updated international treatment recommendations was performed. by the Correlation Network The Netherlands University Medical Centre Ljubljana Slovenia and University of Copenhagen. Denmark Its aim was to present current data from 33 European countries on the existence of national strategies action plans. and guidelines for HCV treatment in the general population and in PWID in particular and to compare them to the same data. collected in 2013 with the purpose to evaluate possible positive trends after the publication of the updated recommendations on. the management of HCV infection in PWID Concomitantly current data on access to treatment with DAAs in different Euro. pean countries were collected by means of a structured questionnaire and the respondents were drawn from a database of the. Correlation Network with most participants from non governmental organizations When comparing the answers on the existence. of the national strategies action plans and clinical guidelines between 2013 and 2016 changes were detected in many European. countries and a positive trend has been noted in recognizing PWID as a group of individuals where strategic action is needed to. increase HCV treatment In the majority of European countries DAAs were reported to be available however restrictions for their. use were reported from a majority of them with fibrosis stage and current or and injecting drug use the two major ones. In order to reduce the number of HCV positive individuals and HCV related disease burden international clinical recommendations. have to be brought into real life practice National strategies action plans and guidelines that specifically address recommenda. tions on HCV testing and treatment in PWID further need to be developed or upgraded and treatment with DAAs should become. available for all HCV positive patients in all European countries in order to eliminate HCV as a public health threat as set out in. the WHO Global health sector strategy on hepatitis 2016 2021. A4 Magdalena,From peer to research, Harris London School of Hygiene and Tropical Medicine London. New developments in hepatitis C treatment can overshadow the crucial role of the community in an effective elimination response. Engagement in care encompassing prevention testing treatment and social structural supports requires more than a bio. medical response In this talk Magdalena reflects on her journey living with and receiving treatment for hepatitis C and how this. informed and impacted on her research practice She also draws on over a decade of research with people living with hepatitis. C and or who use drugs to illustrate the vital role of peers at all stages of the care continuum Researchers clinicians and other. stakeholders must work in collaboration with affected populations and their organisations if the hope of hepatitis C elimination is to. become a reality,A5 From patient to advocate, Anton Basenko International HIV AIDS Alliance in Ukraine Kiev. In this talk Anton reflects on his journey as a street injection drug user living with HIV and Hep C and how Harm Reduction and. Opioid Substitution Treatment changed his mind in understanding the need of access to Hep C treatment and turned him to. advocacy activism for PWID community and other key populations He also pays attention on the special access programs for key. populations and how the civil society and communities advocacy can reduce costs for Hep C diagnostics and treatment stimulate. governmental support and funding for those in need He calls for strong linkages between Hep C treatment and harm reduction. and the role of communities involvement not only as advocates but as peer implementing supporters. A6 Engaging Migrants barriers to testing and treatment. Mesfin Ali Embrace UK Community Support Centre London. The presentation examines some of the barriers for HIV and HCV positive people to get tested and treated with special attention. to exploring ways of engaging migrant populations to be beneficiaries of the services available to them In addition it discusses. how the importance of early testing and treatment can be communicated to this specific target group Methods used include. partnering with other community based organisations in order to reach this vulnerable and high risk group. A7 Thirty years of harm reduction in the Netherlands HCV elimination ahead. Esther Croes Trimbos Institute Utrecht, With regard to hepatitis C HCV The Netherlands has an atypical situation The number of existing HCV infections or the. prevalence in the general population is estimated to be low 0 1 0 4 and even decreasing due to effective prevention. measures However in several risk groups the burden is high Chronic HCV infections are found in first generation migrants from. high HCV endemic countries around 40 of prevalent HCV infections and ever injecting drug users around 28 As many of. these were infected decades ago complications become manifest nowadays The positive news however is that new infections. or the HCV incidence in these risk groups are rare Injecting drugs is not popular in the Netherlands and the availability of harm. reduction measures is high Only in HIV positive MSM a small but significant group new HCV infections are found. The Netherlands is characterised by a pragmatic drug policy For heroin users methadone is available widely and heroin on. prescription for non responders as are needle and syringe exchange programs For heroin and basecoke users drug consump. tion rooms sheltered housing and many other forms of active support and treatment are offered With regards HCV treatment. DAAs are reimbursed for all infected patients irrespective of fibrosis stage or mode of HCV transmission In the last couple of. years the major challenge has been to trace HCV carriers and lead them into care. For migrants local initiatives targeting specific migrant populations have tried to trace chronic HBV and HCV carriers The efforts. were often large compared to the yield For drug users both low threshold open house initiatives e g from the Regenboog Gro. ep and national projects linking addiction care and hospitals like the HCV Break Through projects aimed to increase the number. of chronic HCV patients in DAA treatment With regard to MSM the size and problems have been explored first On a national. level the Hepatitis Initiative Group wrote a National Hepatitis Plan 2016 and the Dutch Health Council advised the Minister of. Health about screening for hepatitis B and C 2016 which both helped in the agenda setting For physicians a clear guideline for. treating hepatitis C has been developed that is updated every 3 months. A8 Hepatitis in prison settings, Heino St ver University of Applied Science Frankfurt.
Globally over 10 million people are held in prisons and other places of detention at any given time People who inject drugs. PWID comprise 10 48 of male and 30 60 of female prisoners The spread of hepatitis C in prisons is clearly driven by. injection drug use with many infected prisoners unaware of their infection status Risk behaviour for acquisition of hepatitis C via. common use of injecting equipment is widespread in many prison settings. In custodial settings effective and efficient prevention models applied in the community are very rarely implemented Only ap. proximately 60 out of more than 10 000 prisons worldwide provide needle exchange Thus HCV prevention is almost exclusively. limited to verbal advice leaflets and other measures directed to cognitive behavioural change Although the outcome of HCV. antiviral treatment is comparable to non substance users and substance users out of prison the uptake for antiviral treatment is. extremely low, Based on a literature review to assess the spread of hepatitis C among prisoners and to learn more about the impact for the. prison system recommendations regarding hepatitis C prevention screening and treatment in prisons will be formulated in this. presentation,A9 Access in EECA countries, Natalia Kravchenko Alliance for Public Health Kiev. In this talk Natalia will present the results of the survey the team work of 11 NGOs from 11 countries in Eastern Europe and. Central Asia EECA which highlights key facts about viral hepatitis epidemics in EECA region possibilities and barriers on acces. sing treatment for general and vulnerable populations in EECA countries She also will share the examples of country response to. the epidemics and civil society role in this process In addition the recommendations for stakeholders based on the conducted. survey will be provided,Parallel Session 1 The treatment cascade. A10 HIV HCV Continuum of Care Model Among Hard to Reach Drug Addicted People in Rome. Meet Test and Treat, Elisabetta Teti Villa Maraini Foundation ONLUS Rome. HIV HCV prevalence among drug addicted people is 15 6 and 80 9 respectively but only 35 and 54 of these ones is. tested It s important to investigate among Hard to Reach drug addicted subjects to better estimate real HIV HCV prevalence and. to improve treatment and health services access Villa Maraini Foundation ONLUS in Rome engaged in the field of drug addiction. since 1976 tested Hard to Reach drug addicted key population and created an information and care pathway to accompany users. from testing to treatment Using a harm reduction model with campers placed in two strategic areas in Rome low threshold. testing was offered to the drug addicted population Overall 1204 subjects were screened on HIV and HCV and 0 9 was found. positive for HIV and 7 48 tested positive for HCV Questionnaires showed that efforts should be focused on improving access. to HIV HCV testing and increase information on transmission In addition there is an urgent need for strategies to link positive. subjects to care, A11 The experiences of GIRUGaia a portugese outreach team.
Teresa Sousa Cl udia Rodrigues Xim ne Rego APDES Porto. GIRUGaia a Portuguese outreach team has been working with drug users DU since 2003 this population is particularly vulne. rable to Hepatitis C HIV and tuberculosis The team aims to achieve the ideal conditions to guarantee this group s access to the. healthcare network since they are many times conditioned by prejudice and stereotypes against DU thus limiting their access to. diagnosis testing and treatment The daily contact with these individuals is vital to establish a relationship of trust and proximity. that usually motivates DU to be part of different therapies This proximity helps the team making the DU co responsible for their. daily intake of methadone antiretroviral or tuberculostatic drugs During this talk APDES will talk about their successes from their. CTP Combined Therapy Program and the ADERE Promotion of DUs adherence to the HCV Therapeutic in an outreach. context project, A12 Directly observed therapy of chronic Hepatitis C with interferon free regimens at a low. threshold drug treatment,Raphael Schubert Suchthilfe Wien Vienna. Directly observed therapy of chronic Hepatitis C with interferon free regimens at a low threshold drug treatment. Background An important subgroup of people who inject drugs PWID receives opioid agonist therapy OAT under direct obser. vation of a physician or nurse at a low threshold drug treatment facility or pharmacy on a daily basis Most of these patients suffer. from psychiatric comorbidities and are reluctant or unable to go to specialized hepatitis centers Our hypothesis was that chronic. hepatitis C in these difficult to treat patients could be optimally managed if modern interferon free regimens were applied together. with OAT under direct observation of a physician or nurse at a low threshold drug treatment facility. Method Eighty seven PWID with chronic hepatitis C and borderline compliance started interferon free treatment of chronic hepati. tis C a low threshold drug treatment facility in Vienna Austria Seven patients were coinfected with HIV and 25 had liver cirrhosis. Patients received antiviral treatment together with OAT under direct observation of a physician or nurse For each patient the. individual treatment regimen was selected according to GT fibrosis stage pretreatment HIV status and current reimbursement. policy of insurances, Result Following this concept of directly observed therapy adherence to antiviral therapy was excellent Only nine scheduled. dates for ingestion of the antiviral therapy in combination with OAT were missed by the 87 patients To this date 66 patients. have completed treatment and a 12 week follow up period Virologic healing of hepatitis C infection could be confirmed in all 66. Conclusion Directly observed therapy of chronic hepatitis C with interferon free all oral regimens at a low threshold drug. treatment facility represents a promising new concept for treatment of patients with borderline compliance receiving OST By this. concept chronic hepatitis C can be cured in a group of difficult to treat patients who are unable to be treated at hepatologic cen. ters It should be stressed that successful treatment of these patients is not only beneficial for themselves but also for the general. population because further transmission of the virus may be prevented. A13 Free Clinic s HCV treatment and peer model, Stephan Bourgeois ZNA and Tonny van Montfoort Free Clinic Antwerp Antwerp. In the last years treatment of hepatitis C has evolved substantially with shorter regimens with almost no side effects and a very. high success rate Moreover ex PWIDS are no any longer considered a special population and can be treated as easily as. other infected patients But there is still a wide gap to bridge in organizing hepatitis C care and treatment. Firstly the very strict reimbursement criteria need to be tackled in Belgium patients can only be treated if they at least have. F2 fibrosis Exceptions are made when patients are co infected with hepatitis B or HIV in that case they are always treated. Secondly for ex PWID patients hepatologists need to be able to stage them and ensure that compliance and lifestyle of patients. are good enough to ensure a positive outcome And lastly prevention after treatment is needed Certainly it is important to stress. taking the necessary measures to avoid re infection Yet prevention of alcohol is also very important within this population where. a lot of patients already have advanced liverfibrosis. To overcome these gaps ZNA a hepatology unit in a large community hospital engaged in an intensive collaboration with the. Free Clinic a low threshold addiction centre This collaboration will be highlighted by some of the addiction clinic co workers. Specifically they will discuss the C buddy system in which a dedicated hepatitis C nurse and a team of peers are linked to pati. ents A specific case study will show the added value in this system of care set up as a not under one roof approach The latest. results of the ZNA database will also be presented. Parallel Session 2 Reach your crowd, A14 MapCrowd A community based tool for advocating toward universal access to hepatitis.
C prevention and care, C line Grillon Julie Bouscaillou Annette Gaudino Bryn Gay Niklas Luhmann Chlo Forette M decins du Monde Paris. Despite the scope and severity of the epidemic caused by HCV the response to reduce the burden of this disease has been very. limited globally Using the Mapcrowd platform a community based tool for HCV advocacy national epidemiological diagnostic. treatment and policy data was collected with specific attention to the situation of people who use drugs PWUD The platform. now displays a consistent dataset on HCV for more than 40 countries building further on an expanding network of contributors. The latest analysis of data collected through the tool was published in the second mapCrowd report Dying at these prices gene. ric HCV cure denied It paints a contrasting picture of the road to HCV elimination According to this data 14 out of 17 countries. in Western Europe established treatment restrictions for people with HCV within their territory DAAs are often limited to those. exhibiting the most severe conditions While people who inject drugs face the highest burden for HCV infection they are more. frequently excluded from health policies and HCV treatment uptake among people who inject drugs remains very low Stigma and. criminalization act as powerful restrictions to access life saving care and treatments. A15 A creative action guide around a Pill Proposal developed by Universities Allied for Es. sential Medicines, Peter Grablitz Universities Allied for Essential Medicines Halle. The Universities Allied for Essential Medicines has created a creative action guide around a Pill Proposal with the specific aim. to increase awareness for high drug prices and the mobilize people to act and protest those high drug prices By staging a false. wedding proposal in the public sphere where the ring is replaced by a pill the actors who are part of the proposal create a context. for the audience to discuss this issue Afterwards the real purpose of the proposal is revealed such as signing a petition letter. inviting the audience to a meeting making donations a Town Hall Meeting with School etc A short film is also attached to this. creative action and uses the same messages Results so far were positive those who witnessed the proposal were more likely to. be interested and were mobilized easily This approach can be easily scaled up and adapted for different contexts. A16 Advocacy video s from drug users in community health action. Antoniu Llort Su rez ARSU Reus, ARSU a Spanish non profit drug user union and advocacy group was founded in 1999 with the specific aim of creating a peer. support group that can fight against prohibitionist drug policies and that can supporting drug users living with HIV and Hepatitis. C They use short video s which they distribute via social media to show the fatal effects of drug users who use drugs in public. spaces and transforms them into safer spots by cleaning them up providing exchange syringe machine s and many more things. A17 Amsterdam MSM Hepatitis C Free,Freke Zuure GGD Public Health Service Amsterdam. In the Netherlands unlike in many other countries current transmission of HCV occurs primarily among HIV positive MSM as HCV. incidence dropped to nearly zero among PWID Since 2000 there has been an unexpected and substantial increase in acute HCV. infections among HIV infected MSM Early testing and treatment of HCV infected HIV positive MSM in combination with upscaling. of preventive measures may curb the HCV epidemic among this population As Part of the MC Free Amsterdam MSM Hepatitis. C Free project aiming to develop an innovative integral strategy to eliminate HCV among MSM in Amsterdam we initiated the. Ctest nl service in its related webapp, Ctest nl is a low cost internet guided home based testing service for HCV RNA home collection testing involving a certified labo.
ratory This service allows men at high risk for HCV infection to take control and test on a regular basis using a highly sensitive. test for the detection of acute HCV infection Home based testing can decrease barriers to testing as it increases convenience. anonymity perceived control over the testing procedure and patient autonomy and control over their own health and decreases. time and efforts needed to visit regular health care facilities In addition the webapp will provide tailored information about risk. practices and related prevention measures including special preventive initiatives such as a sex tool box to help men reduce risk. of infection during group sex,Parallel Session 3 Workshop. A18 On the move Infectious diseases in migrant populations. Julia del Amo National Center for Epidemiology Institute of Health Carlos III Madrid. Denis Oyango EATAN London, Limited access to healthcare for vulnerable migrants in Europe is increasingly worrisome as immigration policies harden Recent. studies have shown large discrepancies between entitlements under international human rights law and the local implementa. tion of care in diverse countries Until now the responsibility for the healthcare of migrants has fallen on emergency services. Generally speaking the care given addresses urgent needs but regrettably underlying chronic conditions are not identified or. worse simply ignored The issues surrounding migrant health are complex and beg institutional leadership and policy direction to. support care workers and managers to better navigate this unchartered territory Further there is a growing body of evidence that. migrants from outside the region are acquiring HCV HIV and TB when they arrive in Europe Is it therefore not a responsibility of. our respective health systems to identify test and treat these vulnerable people. Parallel Session 4 Peer work is crucial, A19 Facilitating access to hepatitis C treatment to people who inject drugs PWID in Georgia. Results of a peer support intervention,Julie Bouscaillou M dicins Du Monde Paris. Georgia faces high HCV rates 7 1 in the general population with a concentrated epidemic among PWID An ambitious. National Program and Elimination Plan was launched in 2015 and M decins du Monde an international NGO and New Vector a. Georgian self support organization of PWID and the medical center Neolab have developed and implemented a peer support in. tervention to facilitate access to and retention of current PWID in first phase of the national treatment program Using rapid testing. and liver elastometry as a noninvasive affordable screening process within a harm reduction service program support intervention. delivered by peer workers before and throughout the treatment period A focal person in the medical center dedicated to media. tion with PWID and peer workers team good results were achieved Results included an uptake in screening 21 increase in a. five month period successful linkage to care a high treatment completed 98 and model replication. A20 HIV HCV TREATMENT ADVOCACY FOR AFRICANS IN THE UNITED KINGDOM. Amie Joof African Eye Birmingham, Black Africans in the United Kingdom are disproportionately affected and infected by HIV and HCV This mingrant community.
accounts for the second largest infection rate in the UK and access to treatment treatment information and support for this group. is lacking To address this gap the African Eye Trust developed a training program in partnership with other HIV organisations to. build the capacity of Africans to advocate for themselves their peers and to increase their knowledge on HIV and HCV treatment. and care A total of 48 African men and women were trained as HIV HCV treatment advocates across England who in turn. have trainer their peers creating a multiplier effect This capacity building training facilitates the dissemination of HIV and HCV. treatment information leads to a possible reduction in poor adherence to medication development of resistance and a possible. reduction in transmission This type of training can be adapted to various other settings with migrant or disadvantaged communi. ties and can produce effective treatment outcomes and meet the goal of universal access to ARV and DAAs.

Related Books

Piano di sanificazione | Caseifici

Piano di sanificazione Caseifici

Sanificazione manuale di servizi igienici, spogliatoi, mense Sanificazione manuale di servizi igienici e spogliatoi Trattamento sanificante e deodorante di pozzetti e canaline Dispenser Sistemi di trattamento calzature Utilizzo giornaliero o al bisogno Utilizzo al bisogno VIGAL Detergente alcalino per pavimenti industriali Con macchina ...



approved crimping tools. use crimp matrix in the tabbed sections to determine correct tool combination. solder all hand crimped terminals. caution: use extreme care on all micro-pack and 150 metri-pack terminals. avoid solder on interface or box area. electrically check repaired terminal for continuity. use kent-moore j-39200-a multimeter or ...



KISI-KISI SOAL UKG PROF UMUM GURU SD KELAS TINGGI NO ... 5 Pedagogik Memanfaatkan teknologi informasi 5.1 Memanfaatkan teknologi informasi dan

SPITFIRE Solo Strings Manual 18.08.02a V3

SPITFIRE Solo Strings Manual 18 08 02a V3

SOLO STRINGS - USER MANUAL PAGE 3 WELCOME Overview Six years ago, Spitfire released Solo Strings, one of our first ever libraries. Since then, we have clocked up over 2,500 hours of sampling experience, so we knew it was time we revisited these essential instruments. They can add individ-uality and definition to big string writing, as well as ...

Social Intelligence Guide for Marketing

Social Intelligence Guide for Marketing

SOCIAL ROI Measuring 8 As social transitions from being a cutting-edge business tool to a business necessity, the focus on ROI for social will increase. Whether your goal is to drive more traffic to your social media sites, build brand awareness and engagement, or drive sales, these 5 best practices can help you drive value from social: 1.

How to Leverage Social Media for Public Relations Success

How to Leverage Social Media for Public Relations Success

3 How to Leverage Social Media for Public Relations Success 1. Introduction Without a doubt, the web and social media are making it easier for businesses to communicate with their publics. At the same time, where there used to be a clear delineation between marketing and public relations, the impact of the web has resulted

The Demand for Urban Housing in the Ivory Coast

The Demand for Urban Housing in the Ivory Coast

No. 25 The Demand for Urban Housing in the Ivory Coast No. 26 The C6te d'Ivoire Living Standards Survey: Design and Implementation No. 27 The Role of Employment and Earnings in Analyzing Levels of Living: A General Methodology with Applications to Malaysia and Thailand No. 28 Analysis of Household Expenditures No. 29 The Distribution of Welfare in C6te d'lvoire in 1985 No. 30 Quality, Quantity ...

Singapore Working Capital Study 2017 - PwC

Singapore Working Capital Study 2017 PwC

Effective working capital management can help companies reduce overall financing costs and release working capital for strategic investments for growth. With strong financial health, companies are better positioned to improve earnings and stay resilient in times of economic uncertainty. Yet, cash flow management has consistently surfaced as a challenge small and medium enterprises (SMEs) in ...

Reflectarray Antennas: Theory, Designs, and Applications

Reflectarray Antennas Theory Designs and Applications

Reflectarray Antennas: Theory, Designs, and Applications Payam Nayeri Colorado School of Mines USA Fan Yang Tsinghua University China Atef Z. Elsherbeni

6. Basic Relativistic Quantum Mechanics

6 Basic Relativistic Quantum Mechanics

6. Basic Relativistic Quantum Mechanics Abstract quantum states projected in configuration space helps bridging the realm from pure mathematics to the applied one thereby allowing for introduction of inertial (Lorentz) frames. It is at a Fence that the theory of special relativity defines transformation properties between Lorentz frames. Communication protocols permit following events in an I ...